The FDA approved Bafiertam for the treatment of relapsing forms of multiple sclerosis (MS) on April 28, 2020.

MenQuadfi, a meningococcal conjugate vaccine, is FDA approved. The FDA granted approval for MenQuadfi on April 23, 2020.

Trodelvy (sacituzumab govitecan-hziy) received accelerated approval on April 22, 2020, for the treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) in adults who have received at least two prior therapies for metastatic disease.

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Pemigatinib on April 17, 2020.

Tucatinib (Tukysa) is an FDA-approved medication for treating HER2-positive breast cancer, specifically in cases where the cancer is metastatic or inoperable.

The U.S. Food and Drug Administration (FDA) granted approval for Selumetinib on April 10, 2020. Selumetinib is used specifically for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

The U.S. Food and Drug Administration (FDA) granted approval to Sevenfact on April 1, 2020.

The U.S. Food and Drug Administration (FDA) approved Ozanimod, marketed under the brand name Zeposia, on March 25, 2020.

The U.S. Food and Drug Administration (FDA) approved Isatuximab, under the brand name Sarclisa, on March 2, 2020. This medication is classified as a CD38 monoclonal antibody and is specifically used to treat multiple myeloma in adults.

The U.S. Food and Drug Administration (FDA) approved Rimegepant, under the brand name Nurtec ODT, on February 27, 2020.

The U.S. Food and Drug Administration (FDA) approved Nexlizet, a combination of bempedoic acid and ezetimibe, on February 26, 2020.

The U.S. Food and Drug Administration (FDA) approved bempedoic acid on February 21, 2020.